Topic: Diabetes - Primary Care
Friday, 06 October 2017
A new UK study shows that 37.8% of people with type 2 diabetes do not take their medications as prescribed. Further analysis showed that people who stick to their prescribed treatments have a 10% lower risk of hospital visits and are 28% less likely to die than people who fail to take their medication.
Wednesday, 12 September 2018
The large randomised controlled ASCEND trial (n=15,480) shows that aspirin reduced the risk of serious vascular events in people with diabetes and no CVD by 12% but also increased the risk of major bleeding by 29% and the authors concluded that absolute benefits were outweighed by bleeding hazard. The trial suggests that aspirin should not be used for primary prevention in patients with diabetes
Tuesday, 10 April 2018
This case study describes the diagnosis and management of 55-year old man with painful diabetic peripheral neuropathy. He is already receiving treatment for his diabetes but is experiencing burning pain in the soles of his feet, especially at night when lying in bed. He has paresthesia and numbness in toes and his sleep is interrupted because of his condition. He also presents with depression and has a number of diabetic complications and co-morbidities.
Category: Case Study
Monday, 23 October 2017
This case study presents an everyday clinical situation for you to review with guidance from an expert in the field.
Sunday, 13 August 2017
An innovative change programme created by Diabetes UK and Ashridge Executive Education, in collaboration with Novo Nordisk who are providing support and funding, has been awarded the prestigious EFMD Excellence in Practice Gold award. The Diabetes UK Clinical Champions programme has been designed to help health professionals in the NHS to tackle failings and complex challenges in diabetes healthcare.
Friday, 06 October 2017
In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.
Thursday, 07 February 2019
Results from the DECLARE study show that the SGLT-2 inhibitor dapagliflozin reduces hospitalisation for heart failure or CV death with no increase in major CV events compared with placebo in a broad population of over 17,000 patients with type 2 diabetes. These are important findings, and more or less consistent with findings noted with other SGLT-2 inhibitors.
Friday, 15 September 2017
Hospitals and GP surgeries are being urged to come together as a ‘national collective’ to raise awareness of a short-term complication of diabetes. They are being urged to take part in Hypo Awareness Week 2017, which runs from Monday 2 October 2 to Sunday 8 October.
Wednesday, 04 April 2018
A landmark longitudinal study suggests that people who are at high risk of developing Type 2 diabetes, and who also have depression, are nearly three times more likely to develop dementia in later life, compared to those with neither condition.